|Awarded On||May 18, 2016|
|Title||Texas Pediatric Patient Derived Xenograft Facility|
|Award Mechanism||Core Facility Support Awards|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Peter J Houghton|
|Cancer Sites||All Sites|
Despite advances in treating childhood cancer, there is a long way to go before the cure rates and the long-term consequences of therapy are acceptable. Developing more effective agents for those children not currently cured, and less toxic therapy to others, poses significant challenges. Additionally, some minority and underserved populations – such as Hispanic populations common across Texas – have outcomes that are worse than the general population, and these populations may be poorly represented in the few clinical trials that are available. To overcome these challenges, we will develop and validate preclinical models that represent the genetic diversity of childhood cancer from the pop...